Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
ARISTOCORT is an injectable small-molecule corticosteroid approved in 1959 for systemic and local anti-inflammatory indications. The exact therapeutic indications are not fully specified in available data, but triamcinolone acetonide (the likely active ingredient based on the brand name) is used for rheumatologic, dermatologic, and allergic conditions. It works through glucocorticoid receptor agonism to suppress immune and inflammatory responses.
This legacy product faces LOE with moderate competitive pressure (30%), signaling a smaller, maintenance-focused commercial team focused on retention rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ARISTOCORT offers limited career growth but stable, specialized expertise in legacy corticosteroid management, reimbursement defense, and generic competition mitigation under Fosun Pharma ownership. Roles are primarily defensive and focused on market share retention rather than innovation or expansion.
Worked on ARISTOCORT at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.